Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-097450
Filing Date
2024-11-13
Accepted
2024-11-13 16:05:28
Documents
95
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0220527-10q_immucell.htm   iXBRL 10-Q 1329957
2 CERTIFICATION ea022052701ex31_immucell.htm EX-31 14679
3 CERTIFICATION ea022052701ex32_immucell.htm EX-32 4806
9 GRAPHIC image_001.jpg GRAPHIC 125917
10 GRAPHIC image_002.jpg GRAPHIC 110388
  Complete submission text file 0001213900-24-097450.txt   8276560

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20240930.xsd EX-101.SCH 59152
5 XBRL CALCULATION FILE iccc-20240930_cal.xml EX-101.CAL 41693
6 XBRL DEFINITION FILE iccc-20240930_def.xml EX-101.DEF 315168
7 XBRL LABEL FILE iccc-20240930_lab.xml EX-101.LAB 563256
8 XBRL PRESENTATION FILE iccc-20240930_pre.xml EX-101.PRE 330703
98 EXTRACTED XBRL INSTANCE DOCUMENT ea0220527-10q_immucell_htm.xml XML 1153794
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12934 | Film No.: 241454048
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)